Fringed virus-like particles in diarrhoeic faeces from calves and dogs

P. Timoney,M. M. Hammond,B. L. Peterson,L. Jones,S. Sieber,L. Carmichael

DOI: https://doi.org/10.1136/VR.113.14.318

1983-10-01

Abstract:

What problem does this paper attempt to address?

Age-Adjusted in-Hospital Mortality in Patients with COVID-19 Infection: Impact of the Presence of Multiple Comorbidities

Nader Tavakoli,Nahid Hashemi-Madani,Mojtaba Malek,Zahra Emami,Alireza Khajavi,Rokhsareh Aghili,Maryam Honardoost,Fereshteh Abdolmaleki,Mohammad E Khamseh

DOI: https://doi.org/10.47176/mjiri.38.60

2024-05-28

Abstract:Background: Mortality has been indicated to be high in patients with underlying diseases. This study aimed to examine the comorbidities is associated with a higher risk of death during the hospital course. Methods: We retrospectively evaluated the risk of in-hospital death in 1368 patients with COVID-19 admitted to 5 academic hospitals in Tehran between February 20 and June 13, 2020. We also assessed the composite end-point of intensive care unit admission, invasive ventilation, and death. The Cox proportional survival model determined the potential comorbidities associated with deaths and serious outcomes. Results: The retrospective follow-up of patients with COVID-19 over 5 months indicated 280 in-hospital deaths. Patients with diabetes (risk ratio (RR), 1.47 (95% CI, 1.10-1.95); P = 0.008) and chronic kidney disease (RR, 1.72 (95% CI, 1.16-2.56); P = 0.007) showed higher in-hospital mortality. Upon stratifying data by age, patients aged ˂65 years showed a greater risk of in-hospital death in the presence of 2 (hazard ratio (HR), 2.68 (95% CI, 1.46-4.95); P = 0.002) or more (HR, 3.47 (95% CI, 1.69-7.12); P = 0.001) comorbidities, compared with those aged ≥ 65 years. Conclusion: Having ≥ 2 comorbidities in nonelderly patients is associated with a greater risk of death during hospitalization. To reduce the mortality of COVID-19 infection, younger patients with underlying diseases should be the focus of attention for prevention strategies.
Treatment of cutaneous leishmaniasis by photodynamic therapy.

J. El-on,M. Katz,L. Weinrauch

DOI: https://doi.org/10.1016/j.jaad.2003.10.676

Abstract:
Mortality Risk Factors among Hospitalized COVID-19 Patients in a Major Referral Center in Iran

Nasser Malekpour Alamdari,Siamak Afaghi,Fatemeh Sadat Rahimi,Farzad Esmaeili Tarki,Sasan Tavana,Alireza Zali,Mohammad Fathi,Sara Besharat,Leyla Bagheri,Fatemeh Pourmotahari,Seyed Sina Naghibi Irvani,Ali Dabbagh,Seyed Ali Mousavi

DOI: https://doi.org/10.1620/tjem.252.73

Abstract:The Coronavirus Disease 2019 (COVID-19) pandemic has killed many people worldwide since December 2019, and Iran has been among the most affected countries. In this retrospective study, we aimed to determine the prognostic factors associated with mortality in COVID-19 patients by analyzing 396 survived and 63 non-survived patients in Shahid Modarres Hospital, Tehran, Iran, from January 30th until April 5th, 2020. As the results, the BMI > 35 (p = 0.0003), lung cancer (p = 0.007), chronic kidney disease (p = 0.002), Immunocompromised condition (p = 0.003), and diabetes (p = 0.018) were more frequently observed in the expired group. The history of statins use was more common in the discharged group (p = 0.002), while there was no significant difference in the drug history of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, nonsteroidal anti-inflammatory drugs, aspirin, and/or steroids, and in the past-year influenza vaccination. Multivariable regression demonstrated rising odds of in-hospital death related with age (odds ratio (OR) = 1.055, p = 0.002), levels of C-reactive protein (CRP) (OR = 2.915, p < 0.001), creatinine (OR = 1.740, p = 0.023), lymphocyte count (OR = 0.999, p = 0.008), and magnesium level (OR = 0.032, p < 0.001) on admission. In conclusion, the patients with older age and higher BMI with lymphopenia, hypomagnesemia, elevated CRP and/or raised creatinine on admission are at higher risk of mortality due to the COVID-19 infection, which requires the physicians to use timely and strong therapeutic measures for such patients.
Common Carrier Provided Network Interfaces

H. Opderbeck

DOI: https://doi.org/10.1007/3-540-08755-9_10

Operating Systems

Abstract:
Impact of comorbidities on patients with COVID-19: A large retrospective study in Zhejiang, China

Chanyuan Ye,Shanyan Zhang,Xiaoli Zhang,Huan Cai,Jueqing Gu,Jiangshan Lian,Yingfeng Lu,Hongyu Jia,Jianhua Hu,Ciliang Jin,Guodong Yu,Yimin Zhang,Jifang Sheng,Yida Yang

DOI: https://doi.org/10.1002/jmv.26183

IF: 20.693

2020-01-01

Journal of Medical Virology

Abstract:Coronavirus disease 2019 (COVID-19) has become a serious public health problem worldwide. Here, we stratified COVID-19 patients based on their comorbidities to assess their risk of serious adverse outcomes. We collected 856 hospitalized cases diagnosed with COVID-19 from 17 January to 7 February 2020, in Zhejiang Province, and analyzed their comorbidities and composite endpoint (including admission to intensive care unit owing to disease progression, shock, invasive ventilation, and death) to determine the relationship between comorbidities and adverse outcomes. The median age of patients was 46 (36-56) years; 439 (51.3%) were men, 242 (28.3%) had comorbidities, and 152 (17.8%) had two or more comorbidities. The most common comorbidity was hypertension (142 [16.6%]), followed by diabetes (64 [7.5%]). Of the 856 patients, there are 154 (18.0%) severe cases. Thirty-two (3.7%) reached composite endpoints, of which 22 (9.1%) were from the comorbidity group and 10 (1.6%) from the non-comorbidity group (P < .001). After adjusting for age and gender status, the risk of reaching the composite endpoint was higher in the group with comorbidity than in that without comorbidity (hazard ratio [HR] 3.04, 95% confidence interval [CI]: 1.40-6.60). HR values for patients with one, two, and three or more comorbidities were 1.61 (95% CI: 0.44-5.91), 3.44 (95% CI: 1.31-9.08), and 6.90 (95% CI: 2.69-17.69), respectively. COVID-19 patients with comorbidities had worse clinical outcomes as compared with those without any comorbidity. The higher the number of comorbidities, the greater was the risk of serious adverse outcomes.
The hepatitis B virus X gene product transactivates the HIV-LTR in vivo.

C. Balsano,O. Billet,M. Bennoun,C. Cavard,A. Zider,G. Grimber,G. Natoli,P. Briand,M. Levrero

DOI: https://doi.org/10.1007/978-3-7091-9312-9_7

Abstract:
Risk Factors for Mortality of Coronavirus Disease 2019 (COVID-19) Patients During the Early Outbreak of COVID-19: a Systematic Review and Meta-Analysis

Yanyan Wu,Hongyu Li,Zhongheng Zhang,Wenhua Liang,Tiansong Zhang,Zhenhua Tong,Xiaozhong Guo,Xingshun Qi

DOI: https://doi.org/10.21037/apm-20-2557

2021-01-01

Annals of Palliative Medicine

Abstract:BACKGROUND:Identification of risk factors for poor prognosis of patients with coronavirus disease 2019 (COVID-19) is necessary to enable the risk stratification and modify the patient's management. Thus, we performed a systematic review and meta-analysis to evaluate the in-hospital mortality and risk factors of death in COVID-19 patients.METHODS:All studies were searched via the PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), VIP, and Wanfang databases. The in-hospital mortality of COVID-19 patients was pooled. Odds ratios (ORs) or mean difference (MD) with 95% confidence intervals (CIs) were calculated for evaluation of risk factors.RESULTS:A total of 80 studies were included with a pooled in-hospital mortality of 14% (95% CI: 12.2-15.9%). Older age (MD =13.32, 95% CI: 10.87-15.77; P<0.00001), male (OR =1.66, 95% CI: 1.37-2.01; P<0.00001), hypertension (OR =2.67, 95% CI: 2.08-3.43; P<0.00001), diabetes (OR =2.14, 95% CI: 1.76-2.6; P<0.00001), chronic respiratory disease (OR =3.55, 95% CI: 2.65-4.76; P<0.00001), chronic heart disease/cardiovascular disease (OR =3.15, 95% CI: 2.43-4.09; P<0.00001), elevated levels of high-sensitive cardiac troponin I (MD =66.65, 95% CI: 16.94-116.36; P=0.009), D-dimer (MD =4.33, 95% CI: 2.97-5.68; P<0.00001), C-reactive protein (MD =48.03, 95% CI: 27.79-68.27; P<0.00001), and a decreased level of albumin at admission (MD =-3.98, 95% CI: -5.75 to -2.22; P<0.0001) are associated with higher risk of death. Patients who developed acute respiratory distress syndrome (OR =62.85, 95% CI: 29.45-134.15; P<0.00001), acute cardiac injury (OR =25.16, 95% CI: 6.56-96.44; P<0.00001), acute kidney injury (OR =22.86, 95% CI: 4.60-113.66; P=0.0001), and septic shock (OR =24.09, 95% CI: 4.26-136.35; P=0.0003) might have a higher in-hospital mortality.CONCLUSIONS:Advanced age, male, comorbidities, increased levels of acute inflammation or organ damage indicators, and complications are associated with the risk of mortality in COVID-19 patients, and should be integrated into the risk stratification system.
Non-COVID-19 hospitalization and mortality during the COVID-19 pandemic in Iran: a longitudinal assessment of 41 million people in 2019–2022

Mahya Razimoghadam,Mehdi Yaseri,Mehdi Rezaee,Aliakbar Fazaeli,Rajabali Daroudi

DOI: https://doi.org/10.1186/s12889-024-17819-0

IF: 4.5

2024-02-05

BMC Public Health

Abstract:Abstract Background During a COVID-19 pandemic, it is imperative to investigate the outcomes of all non-COVID-19 diseases. This study determines hospital admissions and mortality rates related to non-COVID-19 diseases during the COVID-19 pandemic among 41 million Iranians. Method This nationwide retrospective study used data from the Iran Health Insurance Organization. From September 23, 2019, to Feb 19, 2022, there were four study periods: pre-pandemic (Sept 23-Feb 19, 2020), first peak (Mar 20-Apr 19, 2020), first year (Feb 20, 2020-Feb 18, 2021), and the second year (Feb 19, 2021-Feb 19, 2022) following the pandemic. Cause-specific hospital admission and in-hospital mortality are the main outcomes analyzed based on age and sex. Negative binomial regression was used to estimate the monthly adjusted Incidence Rate Ratio (IRR) to compare hospital admission rates in aggregated data. A logistic regression was used to estimate the monthly adjusted in-hospital mortality Odds Ratio (OR) for different pandemic periods. Results During the study there were 6,522,114 non-COVID-19 hospital admissions and 139,679 deaths. Prior to the COVID-19 outbreak, the standardized hospital admission rate per million person-month was 7115.19, which decreased to 2856.35 during the first peak (IRR 0.40, [0.25–0.64]). In-hospital mortality also increased from 20.20 to 31.99 (OR 2.05, [1.97–2.13]). All age and sex groups had decreased admission rates, except for females at productive ages. Two years after the COVID-19 outbreak, the non-COVID-19 hospital admission rate (IRR 1.25, [1.13–1.40]) and mortality rate (OR 1.05, [1.04–1.07]) increased compared to the rates before the pandemic. The respiratory disease admission rate decreased in the first (IRR 0.23, [0.17–0.31]) and second years (IRR 0.35, [0.26–0.47] compared to the rate before the pandemic. There was a significant reduction in hospitalizations for pneumonia (IRR 0.30, [0.21–0.42]), influenza (IRR 0.04, [0.03–0.06]) and COPD (IRR 0.39, [0.23–0.65]) during the second year. There was a significant and continuous rise in the hematological admission rate during the study, reaching 186.99 per million person-month in the second year, reflecting an IRR of 2.84 [2.42–3.33] compared to the pre-pandemic period. The mortality rates of mental disorders (OR 2.15, [1.65–2.78]) and musculoskeletal (OR 1.48, [1.20–1.82), nervous system (OR 1.42, [1.26–1.60]), metabolic (OR 1.99, [1.80–2.19]) and circulatory diseases (OR 1.35, [1.31–1.39]) increased in the second year compare to pre-pandemic. Myocardial infarction (OR 1.33, [1.19–1.49]), heart failure (OR 1.59, [1.35–1.87]) and stroke (OR 1.35, [1.24–1.47]) showed an increase in mortality rates without changes in hospitalization. Conclusions In the era of COVID-19, the changes seem to have had a long-term effect on non-COVID-19 diseases. Countries should prepare for similar crises in the future to ensure medical services are not suspended.

public, environmental & occupational health
Prevalence and predictors of death and severe disease in patients hospitalized due to COVID-19: A comprehensive systematic review and meta-analysis of 77 studies and 38,000 patients

Kunchok Dorjee,Hyunju Kim,Elizabeth Bonomo,Rinchen Dolma

DOI: https://doi.org/10.1371/journal.pone.0243191

IF: 3.7

2020-12-07

PLoS ONE

Abstract:Introduction: Progression of COVID-19 to severe disease and death is insufficiently understood. Objective: Summarize the prevalence of risk factors and adverse outcomes and determine their associations in COVID-19 patients who were hospitalized. Methods: We searched Medline, Embase and Web of Science for case-series and observational studies of hospitalized COVID-19 patients through August 31, 2020. Data were analyzed by fixed-effects meta-analysis using Shore's adjusted confidence intervals to address heterogeneity. Results: Seventy-seven studies comprising 38906 hospitalized patients met inclusion criteria; 21468 from the US-Europe and 9740 from China. Overall prevalence of death [% (95% CI)] from COVID-19 was 20% (18-23%); 23% (19-27%) in the US and Europe and 11% (7-16%) for China. Of those that died, 85% were aged≥60 years, 66% were males, and 66%, 44%, 39%, 37%, and 27% had hypertension, smoking history, diabetes, heart disease, and chronic kidney disease (CKD), respectively. The case fatality risk [%(95% CI)] were 52% (46-60) for heart disease, 51% (43-59) for COPD, 48% (37-63) for chronic kidney disease (CKD), 39% for chronic liver disease (CLD), 28% (23-36%) for hypertension, and 24% (17-33%) for diabetes. Summary relative risk (sRR) of death were higher for age≥60 years [sRR = 3.6; 95% CI: 3.0-4.4], males [1.3; 1.2-1.4], smoking history [1.3; 1.1-1.6], COPD [1.7; 1.4-2.0], hypertension [1.8; 1.6-2.0], diabetes [1.5; 1.4-1.7], heart disease [2.1; 1.8-2.4], CKD [2.5; 2.1-3.0]. The prevalence of hypertension (55%), diabetes (33%), smoking history (23%) and heart disease (17%) among the COVID-19 hospitalized patients in the US were substantially higher than that of the general US population, suggesting increased susceptibility to infection or disease progression for the individuals with comorbidities. Conclusions: Public health screening for COVID-19 can be prioritized based on risk-groups. Appropriately addressing the modifiable risk factors such as smoking, hypertension, and diabetes could reduce morbidity and mortality due to COVID-19; public messaging can be accordingly adapted.
Clinical and imaging features of patients with COVID-19 in a double-center cohort study

Mohsen Gholinataj Jelodar,Mahshid Nadershahbaz,Samaneh Mirzaei,Mahdi Montazerolhodjah,Fatemeh Saghafi

DOI: https://doi.org/10.3855/jidc.17817

2024-03-31

The Journal of Infection in Developing Countries

Abstract:Introduction: There is extensive published data on coronavirus disease 2019 (COVID-19). However, information on the effective factors that improve the pulmonary involvement of COVID-19 patients, and long-term clinical and imaging follow-up of these patients is limited. Methodology: This is a prospective cohort study on patients with COVID-19 who were hospitalized in two major academic hospitals in Yazd, Iran. The correlation between the baseline demographic and clinical/para-clinical data with the imaging resolution status at day 60 was assessed. Results: 122 patients, including 65 males, with an average age of 53.43 years participated in this study. Age, gender, baseline oxygen saturation (O2Sat), and the percentage of lung involvement were the main prognostic factors. Our results suggest that with every year increase in age, the probability of complete imaging resolution decreases by 6.4%. In addition, women are 2.07 times more likely to recover completely. Moreover, each percent increase of baseline O2Sat makes the patients 15.4% more likely to fully recover. As the patients’ shortness of breath increases, the probability of recovery decreases by 9.8%.;56.7% of patients who did not recover after 60 days had persistent shortness of breath, while only 21% of those who recovered had symptoms of dyspnea after day 60. Conclusions: Age, gender, baseline O2Sat, percentage of lung involvement, and shortness of breath were identified as the main risk factors in the recovery of patients with COVID-19. Long-term follow-up of patients with COVID-19, especially patients with high-risk factors, is necessary.

infectious diseases
A multicenter study of severity and prognosis of symptomatic COVID‐19 in end‐stage renal disease and non‐dialysis patients in East of Iran

Tara Mohsenzadeh,Masood Ziaee,Hamid Salehiniya,Hossein Mohsenzadeh,Amin Mirsani,Vajehallah Raeesi

DOI: https://doi.org/10.1002/iid3.1188

2024-03-10

Immunity Inflammation and Disease

Abstract:Based on the results of this study, it is plausible to suggest a hypothesis of greater severity and worse prognosis of COVID‐19 in end‐stage renal disease patients. Underlying comorbidities, such as liver disorders or more severe clinical symptoms like altered consciousness, may also be indicative of a worse prognosis in dialysis patients with COVID‐19. Objectives This study aimed to assess the severity and related factors of symptomatic COVID‐19 in end‐stage renal disease (ESRD) patients from several centers in Eastern Iran. Methods In this retrospective cohort study, after obtaining ethical approval, 410 patients diagnosed with COVID‐19 were included for analysis. Patients were categorized into two groups based on their dialysis status: the dialysis group (ESRD patients undergoing hemodialysis) and the non‐dialysis group (those without chronic dialysis). Demographic information, clinical symptoms, laboratory tests at admission, length of hospitalization, ICU admission, need for mechanical ventilation, and mortality data were extracted from their medical records and entered into researcher‐developed checklists. Results In this multicenter study, 104 dialysis patients with a mean age of 64.81 ± 16.04 were compared to 316 non‐dialysis patients with a mean age of 60.92 ± 17.89. Patients were similar in terms of age and gender, but a higher percentage of the dialysis group was aged over 65 years (p = .008). Altered consciousness, dyspnea, headache, myalgia, anorexia, and cough were statistically significantly more common in the dialysis group when evaluating clinical symptoms (p

immunology
Risk factors for COVID-19 progression and mortality in hospitalized patients without pre-existing comorbidities

Weifang Liu,Chengzhang Yang,Yuan-Gao Liao,Feng Wan,Lijin Lin,Xuewei Huang,Bing-Hong Zhang,Yufeng Yuan,Peng Zhang,Xiao-Jing Zhang,Zhi-Gang She,Lei Wang,Hongliang Li,Yuan-gao Liao

DOI: https://doi.org/10.1016/j.jiph.2021.11.012

IF: 7.537

2022-01-01

Journal of Infection and Public Health

Abstract:BACKGROUND: Coronavirus disease 2019 (COVID-19) pandemic continues to escalate intensively worldwide. Massive studies on general populations with SARS-CoV-2 infection have revealed that pre-existing comorbidities were a major risk factor for the poor prognosis of COVID-19. Notably, 49-75% of COVID-19 patients had no comorbidities, but this cohort would also progress to severe COVID-19 or even death. However, risk factors contributing to disease progression and death in patients without chronic comorbidities are largely unknown; thus, specific clinical interventions for those patients are challenging.METHODS: A multicenter, retrospective study based on 4806 COVID-19 patients without chronic comorbidities was performed to identify potential risk factors contributing to COVID-19 progression and death using LASSO and a stepwise logistic regression model.RESULTS: Among 4806 patients without pre-existing comorbidities, the proportions with severe progression and mortality were 34.29% and 2.10%, respectively. The median age was 47.00 years [interquartile range, 36.00-56.00], and 2162 (44.99%) were men. Among 51 clinical parameters on admission, age ≥ 47, oxygen saturation < 95%, increased lactate dehydrogenase, neutrophil count, direct bilirubin, creatine phosphokinase, blood urea nitrogen levels, dyspnea, increased blood glucose and prothrombin time levels were associated with COVID-19 mortality in the entire cohort. Of the 3647 patients diagnosed with non-severe COVID-19 on admission, 489(13.41%) progressed to severe disease. The risk factors associated with COVID-19 progression from non-severe to severe illness were increased procalcitonin levels, SpO2 < 95%, age ≥ 47, increased LDH, activated partial thromboplastin time levels, decreased high-density lipoprotein cholesterol levels, dyspnea and increased D-dimer levels.CONCLUSIONS: COVID-19 patients without pre-existing chronic comorbidities have specific traits and disease patterns. COVID-19 accompanied by severe bacterial infections, as indicated by increased procalcitonin levels, was highly associated with disease progression from non-severe to severe. Aging, impaired respiratory function, coagulation dysfunction, tissue injury, and lipid metabolism dysregulation were also associated with disease progression. Once factors for multi-organ damage were elevated and glucose increased at admission, these findings indicated a higher risk for mortality. This study provides information that helps to predict COVID-19 prognosis specifically in patients without chronic comorbidities.

infectious diseases,public, environmental & occupational health
Risk factors prediction, clinical outcomes, and mortality in COVID-19 patients

Roohallah Alizadehsani,Zahra Alizadeh Sani,Mohaddeseh Behjati,Zahra Roshanzamir,Sadiq Hussain,Niloofar Abedini,Fereshteh Hasanzadeh,Abbas Khosravi,Afshin Shoeibi,Mohamad Roshanzamir,Pardis Moradnejad,Saeid Nahavandi,Fahime Khozeimeh,Assef Zare,Maryam Panahiazar,U Rajendra Acharya,Sheikh Mohammed Shariful Islam

DOI: https://doi.org/10.1002/jmv.26699

Abstract:Preventing communicable diseases requires understanding the spread, epidemiology, clinical features, progression, and prognosis of the disease. Early identification of risk factors and clinical outcomes might help in identifying critically ill patients, providing appropriate treatment, and preventing mortality. We conducted a prospective study in patients with flu-like symptoms referred to the imaging department of a tertiary hospital in Iran between March 3, 2020, and April 8, 2020. Patients with COVID-19 were followed up after two months to check their health condition. The categorical data between groups were analyzed by Fisher's exact test and continuous data by Wilcoxon rank-sum test. Three hundred and nineteen patients (mean age 45.48 ± 18.50 years, 177 women) were enrolled. Fever, dyspnea, weakness, shivering, C-reactive protein, fatigue, dry cough, anorexia, anosmia, ageusia, dizziness, sweating, and age were the most important symptoms of COVID-19 infection. Traveling in the past 3 months, asthma, taking corticosteroids, liver disease, rheumatological disease, cough with sputum, eczema, conjunctivitis, tobacco use, and chest pain did not show any relationship with COVID-19. To the best of our knowledge, a number of factors associated with mortality due to COVID-19 have been investigated for the first time in this study. Our results might be helpful in early prediction and risk reduction of mortality in patients infected with COVID-19.
Patterns of case fatality and hospitalization duration among nearly 1 million hospitalized COVID-19 patients covered by Iran Health Insurance Organization (IHIO) over two years of pandemic: An analysis of associated factors

Reza Mehrizi,Ali Golestani,Mohammad-Reza Malekpour,Hossein Karami,Mohammad Mahdi Nasehi,Mohammad Effatpanah,Mehdi Rezaee,Zahra Shahali,Ali Akbari Sari,Rajabali Daroudi

DOI: https://doi.org/10.1371/journal.pone.0298604

IF: 3.7

2024-02-23

PLoS ONE

Abstract:Background Different populations and areas of the world experienced diverse COVID-19 hospitalization and mortality rates. Claims data is a systematically recorded source of hospitalized patients’ information that could be used to evaluate the disease management course and outcomes. We aimed to investigate the hospitalization and mortality patterns and associated factors in a huge sample of hospitalized patients. Methods In this retrospective registry-based study, we utilized claim data from the Iran Health Insurance Organization (IHIO) consisting of approximately one million hospitalized patients across various hospitals in Iran over a 26-month period. All records in the hospitalization dataset with ICD-10 codes U07.1/U07.2 for clinically/laboratory confirmed COVID-19 were included. In this study, a case referred to one instance of a patient being hospitalized. If a patient experienced multiple hospitalizations within 30 days, those were aggregated into a single case. However, if hospitalizations had longer intervals, they were considered independent cases. The primary outcomes of study were general and intensive care unit (ICU) hospitalization periods and case fatality rate (CFR) at the hospital. Besides, various demographic and hospitalization-associated factors were analyzed to derive the associations with study outcomes using accelerated failure time (AFT) and logistic regression models. Results A total number of 1 113 678 admissions with COVID-19 diagnosis were recorded by IHIO during the study period, defined as 917 198 cases, including 51.9% females and 48.1% males. The 61–70 age group had the highest number of cases for both sexes. Among defined cases, CFR was 10.36% (95% CI: 10.29–10.42). The >80 age group had the highest CFR (26.01% [95% CI: 25.75–26.27]). The median of overall hospitalization and ICU days were 4 (IQR: 3–7) and 5 (IQR: 2–8), respectively. Male patients had a significantly higher risk for mortality both generally (odds ratio (OR) = 1.36 [1.34–1.37]) and among ICU admitted patients (1.12 [1.09–1.12]). Among various insurance funds, Foreign Citizens had the highest risk of death both generally (adjusted OR = 2.06 [1.91–2.22]) and in ICU (aOR = 1.71 [1.51–1.92]). Increasing age groups was a risk of longer hospitalization, and the >80 age group had the highest risk for overall hospitalization period (median ratio = 1.52 [1.51–1.54]) and at ICU (median ratio = 1.17 [1.16–1.18]). Considering Tehran as the reference province, Sistan and Balcuchestan (aOR = 1.4 [1.32–1.48]), Alborz (aOR = 1.28 [1.22–1.35]), and Khorasan Razavi (aOR = 1.24 [1.20–1.28]) were the provinces with the highest risk of mortality in hospitalized patients. Conclusion Hospitalization data unveiled mortality and duration associations with variables, highlighting provincial outcome disparities in Iran. Using enhanced registry systems in conjunction with other studies, empowers policymakers with evidence for optimizing resource allocation and fortifying healthcare system resilience against future health challenges.

multidisciplinary sciences
COVID-19 Predictors of Morbidity and Mortality

Gurdeep Singh,Caroline M Tuczinski,Reshma S Thatipelly,Habib Aminy,Numair Tahir

DOI: https://doi.org/10.7759/cureus.59017

2024-04-25

Cureus

Abstract:Background and objectives There are multiple factors and comorbid conditions that can impact the outcomes of COVID-19. This study aimed to assess how patients with certain comorbidities and risk factors were affected by COVID-19. Methodology This retrospective study involved 578 inpatients who presented to the emergency room (ER) due to COVID-19 infection, diagnosed with COVID-19 between 2020 and 2021. This research takes note of COVID-19 severity, particularly in individuals with comorbidities such as chronic obstructive pulmonary disease (COPD), diabetes mellitus (DM), chronic kidney disease (CKD), coronary artery disease (CAD), and hypertension. Results A two-sample t-test found that age was a significant factor affecting hospital length of stay (LOS) and mortality. An ANOVA analysis of race, DM, and CAD showed a significant effect on LOS (p-values = 0.005, 0.01, and 0.01, respectively) but not on mortality and intubation. White patients had an increased LOS compared to other ethnicities. CKD and hypertension significantly affect mortality and LOS. However, COPD did significantly influence all three variables: mortality, intubation, and LOS (p-values = 0.005, 0.013, and 0.01, respectively). A multiple ANOVA test showed that COPD, hypertension, and CKD had a significant effect on mortality, intubation, and LOS (p-values = 0.014, 0.004, and 0.01, respectively). DM showed weaker significance on mortality, intubation, and LOS (p-value = 0.108). Conclusions Patients with all three comorbid conditions (COPD, hypertension, and CKD) had increased length of stay, intubation, and mortality; thus, appropriate measures including close observation and early intervention may be necessary to prevent mortality in these patients.
The absence of an 8-desaturases in rat liver: a reevaluation of optional pathways for the metabolism of linoleic and linolenic acids.

H. Sprecher,C. J. Lee

DOI: https://doi.org/10.1016/0005-2760(75)90067-3

1975-04-18

Biochimica et Biophysica Acta

Abstract:
Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan

Xiaochen Li,Shuyun Xu,Muqing Yu,Ke Wang,Yu Tao,Ying Zhou,Jing Shi,Min Zhou,Bo Wu,Zhenyu Yang,Cong Zhang,Junqing Yue,Zhiguo Zhang,Harald Renz,Xiansheng Liu,Jungang Xie,Min Xie,Jianping Zhao

DOI: https://doi.org/10.1016/j.jaci.2020.04.006

IF: 14.29

2020-07-01

Journal of Allergy and Clinical Immunology

Abstract:BackgroundIn December 2019, COVID-19 outbreak occurred in Wuhan. Data on the clinical characteristics and outcomes of patients with severe COVID-19 are limited.ObjectiveThe severity on admission, complications, treatment, and outcomes of COVID-19 patients were evaluated.MethodsPatients with COVID-19 admitted to Tongji Hospital from January 26, 2020 to February 5, 2020 were retrospectively enrolled and followed-up until March 3, 2020. Potential risk factors for severe COVID-19 were analyzed by a multivariable binary logistic model. Cox proportional hazard regression model was used for survival analysis in severe patients.ResultsWe identified 269 (49.1%) of 548 patients as severe cases on admission. Elder age, underlying hypertension, high cytokine levels (IL-2R, IL-6, IL-10, and TNF-a), and high LDH level were significantly associated with severe COVID-19 on admission. The prevalence of asthma in COVID-19 patients was 0.9%, markedly lower than that in the adult population of Wuhan. The estimated mortality was 1.1% in nonsevere patients and 32.5% in severe cases during the average 32 days of follow-up period. Survival analysis revealed that male, elder age, leukocytosis, high LDH level, cardiac injury, hyperglycemia, and high-dose corticosteroid use were associated with death in patients with severe COVID-19.ConclusionsPatients with elder age, hypertension, and high LDH level need careful observation and early intervention to prevent the potential development of severe COVID-19. Severe male patients with heart injury, hyperglycemia, and high-dose corticosteroid use may have high risk of death.

immunology,allergy
SIMulation of Medication Error induced by Clinical Trial drug labeling: the SIMME-CT study.

Cécile Dollinger,V. Schwiertz,L. Sarfati,C. Gourc-Berthod,M. Guédat,C. Alloux,N. Vantard,N. Gauthier,Sophie He,E. Kiouris,A. Caffin,Delphine Bernard,F. Ranchon,C. Rioufol

DOI: https://doi.org/10.1093/intqhc/mzw025

2016-06-01

International Journal for Quality in Health Care

Abstract:OBJECTIVE To assess the impact of investigational drug labels on the risk of medication error in drug dispensing. DESIGN A simulation-based learning program focusing on investigational drug dispensing was conducted. SETTING The study was undertaken in an Investigational Drugs Dispensing Unit of a University Hospital of Lyon, France. PARTICIPANTS Sixty-three pharmacy workers (pharmacists, residents, technicians or students) were enrolled. INTERVENTION Ten risk factors were selected concerning label information or the risk of confusion with another clinical trial. Each risk factor was scored independently out of 5: the higher the score, the greater the risk of error. From 400 labels analyzed, two groups were selected for the dispensing simulation: 27 labels with high risk (score ≥3) and 27 with low risk (score ≤2). Each question in the learning program was displayed as a simulated clinical trial prescription. MAIN OUTCOME MEASURE Medication error was defined as at least one erroneous answer (i.e. error in drug dispensing). For each question, response times were collected. RESULTS High-risk investigational drug labels correlated with medication error and slower response time. Error rates were significantly 5.5-fold higher for high-risk series. Error frequency was not significantly affected by occupational category or experience in clinical trials. CONCLUSIONS SIMME-CT is the first simulation-based learning tool to focus on investigational drug labels as a risk factor for medication error. SIMME-CT was also used as a training tool for staff involved in clinical research, to develop medication error risk awareness and to validate competence in continuing medical education.
Correlation between Arterial Blood Oxygen Saturation, Underlying Diseases and Clinical Signs of COVID-19 Patients with Their Final Outcome

Ebrahim Nasiri,Masoumeh Zakeri Azizi,Kazem Aghajanipoor

DOI: https://doi.org/10.18502/tbsrj.v3i4.7796

2021-11-23

Tabari Biomedical Student Research Journal

Abstract:Introduction: COVID-19 can rapidly cause lung damage and severe respiratory distress and subsequently reduce oxygen saturation (SPO2), especially in generally ill patients, which may be exacerbated if severe clinical symptoms or underlying diseases are added. This may lead to deterioration of blood oxygenation or even increase the risk of death when severe clinical symptoms or underlying diseases are present. Therefore, the aim of this study was to Evaluation of the relationship between arterial blood oxygen saturation level and outcome in COVID-19 patients.Material and Methods: A cross-sectional study of 250 patients referred to Imam Sari Hospital with symptoms of respiratory infection, gastrointestinal, and general symptoms in January 2020 to September 2020. Data were analyzed using SPSS version 26.Results: 27 out of 250 patients died. There is a positive correlation between systemic patient, SPO2 and less than 90% with death results (P<0/02). Patients with heart disease (44.4%), cancer (30.1%), diabetes (11.1%), cerebrovascular accident (18.5%) died (P<0/05). There was no positive correlation between weakness, fever, dyspnea, nausea, and diarrhea and appetite loss with death.Conclusion: Based on the present study, it was found that patients whose clinical symptoms were associated with underlying disease and SPO2 to a severe and critical degree had a higher risk of adverse outcome such as death. People with underlying conditions such as DM, CVD, HTN, and a history of angiography and cancer are also more likely to die due to COVID-19. Most deaths in the present study had low SPO2 at before admission, indicating a strong association between patient mortality and severity of lung involvement and low SPO2.
Age-Related Risk Factors and Complications of Patients With COVID-19: A Population-Based Retrospective Study

Han Zhang,Yingying Wu,Yuqing He,Xingyuan Liu,Mingqian Liu,Yuhong Tang,Xiaohua Li,Guang Yang,Gang Liang,Shabei Xu,Minghuan Wang,Wei Wang

DOI: https://doi.org/10.3389/fmed.2021.757459

IF: 3.9

2022-01-11

Frontiers in Medicine

Abstract:Objective: To study the differences in clinical characteristics, risk factors, and complications across age-groups among the inpatients with the coronavirus disease 2019 (COVID-19). Methods: In this population-based retrospective study, we included all the positive hospitalized patients with COVID-19 at Wuhan City from December 29, 2019 to April 15, 2020, during the first pandemic wave. Multivariate logistic regression analyses were used to explore the risk factors for death from COVID-19. Canonical correlation analysis (CCA) was performed to study the associations between comorbidities and complications. Results: There are 36,358 patients in the final cohort, of whom 2,492 (6.85%) died. Greater age (odds ration [ OR ] = 1.061 [95% CI 1.057–1.065], p < 0.001), male gender ( OR = 1.726 [95% CI 1.582–1.885], p < 0.001), alcohol consumption ( OR = 1.558 [95% CI 1.355–1.786], p < 0.001), smoking ( OR = 1.326 [95% CI 1.055–1.652], p = 0.014), hypertension ( OR = 1.175 [95% CI 1.067–1.293], p = 0.001), diabetes ( OR = 1.258 [95% CI 1.118–1.413], p < 0.001), cancer ( OR = 1.86 [95% CI 1.507–2.279], p < 0.001), chronic kidney disease (CKD) ( OR = 1.745 [95% CI 1.427–2.12], p < 0.001), and intracerebral hemorrhage (ICH) ( OR = 1.96 [95% CI 1.323–2.846], p = 0.001) were independent risk factors for death from COVID-19. Patients aged 40–80 years make up the majority of the whole patients, and them had similar risk factors with the whole patients. For patients aged <40 years, only cancer ( OR = 17.112 [95% CI 6.264–39.73], p < 0.001) and ICH ( OR = 31.538 [95% CI 5.213–158.787], p < 0.001) were significantly associated with higher odds of death. For patients aged >80 years, only age ( OR = 1.033 [95% CI 1.008–1.059], p = 0.01) and male gender ( OR = 1.585 [95% CI 1.301–1.933], p < 0.001) were associated with higher odds of death. The incidence of most complications increases with age, but arrhythmias, gastrointestinal bleeding, and sepsis were more common in younger deceased patients with COVID-19, with only arrhythmia reaching statistical difference ( p = 0.039). We found a relatively poor correlation between preexisting risk factors and complications. Conclusions: Coronavirus disease 2019 are disproportionally affected by age for its clinical manifestations, risk factors, complications, and outcomes. Prior complications have little effect on the incidence of extrapulmonary complications.

medicine, general & internal

Fringed virus-like particles in diarrhoeic faeces from calves and dogs

Age-Adjusted in-Hospital Mortality in Patients with COVID-19 Infection: Impact of the Presence of Multiple Comorbidities

Treatment of cutaneous leishmaniasis by photodynamic therapy.

Mortality Risk Factors among Hospitalized COVID-19 Patients in a Major Referral Center in Iran

Common Carrier Provided Network Interfaces

Impact of comorbidities on patients with COVID-19: A large retrospective study in Zhejiang, China

The hepatitis B virus X gene product transactivates the HIV-LTR in vivo.

Risk Factors for Mortality of Coronavirus Disease 2019 (COVID-19) Patients During the Early Outbreak of COVID-19: a Systematic Review and Meta-Analysis

Non-COVID-19 hospitalization and mortality during the COVID-19 pandemic in Iran: a longitudinal assessment of 41 million people in 2019–2022

Prevalence and predictors of death and severe disease in patients hospitalized due to COVID-19: A comprehensive systematic review and meta-analysis of 77 studies and 38,000 patients

Clinical and imaging features of patients with COVID-19 in a double-center cohort study

A multicenter study of severity and prognosis of symptomatic COVID‐19 in end‐stage renal disease and non‐dialysis patients in East of Iran

Risk factors for COVID-19 progression and mortality in hospitalized patients without pre-existing comorbidities

Risk factors prediction, clinical outcomes, and mortality in COVID-19 patients

Patterns of case fatality and hospitalization duration among nearly 1 million hospitalized COVID-19 patients covered by Iran Health Insurance Organization (IHIO) over two years of pandemic: An analysis of associated factors

COVID-19 Predictors of Morbidity and Mortality

The absence of an 8-desaturases in rat liver: a reevaluation of optional pathways for the metabolism of linoleic and linolenic acids.

Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan

SIMulation of Medication Error induced by Clinical Trial drug labeling: the SIMME-CT study.

Correlation between Arterial Blood Oxygen Saturation, Underlying Diseases and Clinical Signs of COVID-19 Patients with Their Final Outcome

Age-Related Risk Factors and Complications of Patients With COVID-19: A Population-Based Retrospective Study